.png){kind=icon}
Return
Hepatitis C
.png){kind=icon}
PRE
AI
DOI：10.1016/S0140-6736(23)01320-X.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Hepatitis C virus (HCV) is a hepatotropic RNA virus that can cause acute and chronic hepatitis, with progressive liver damage resulting in cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In 2016, WHO called for the elimination of HCV infection as a public health threat by 2030. Despite some progress, an estimated 57 million people were living with HCV infection in 2020, and 300 000 HCV-related deaths occur per year. The development of direct-acting antiviral therapy has revolutionised clinical care and generated impetus for elimination, but simplified and broadened HCV screening, enhanced linkage to care, and higher coverage of treatment and primary prevention strategies are urgently required.
Keywords:
HIV-POSITIVE MEN
HCV GENOTYPE 1
VIRUS-INFECTION
INJECT DRUGS
SINGLE-ARM
OPEN-LABEL
SPONTANEOUS CLEARANCE
GLOBAL PREVALENCE
PHASE 4
SOFOSBUVIR
Journal
IF:
88.5
Papers:
5.4W
Citations:
34.8W
Organization
Cited Papers
ShareSaveShareSaveShareSaveMorbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients.png)
GASTROENTEROLOGY
GASTROENTEROLOGYIF25.1
PREAI
ShareSaveShareSaveEvaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in PrisonsHEPATOLOGY
OAAI
HEPATOLOGYIF15.8
OAAIShareSavePregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohortLIVER INTERNATIONAL
LIVER INTERNATIONALIF5.2
PREAI
ShareSave
View more